Cyclerion Therapeutics, Inc. (CYCN)

NASDAQ: CYCN · IEX Real-Time Price · USD
3.080
-0.020 (-0.64%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Company Description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.

Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.

It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders.

It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms.

The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Dr. Regina Graul Ph.D.

Contact Details

Address:
301 Binney Street
Cambridge, Massachusetts 02142
United States
Phone 617-621-7722
Website cyclerion.com

Stock Details

Ticker Symbol CYCN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001755237
CUSIP Number 23255M105
ISIN Number US23255M2044
Employer ID 83-1895370
SIC Code 2834

Key Executives

Name Position
Dr. Regina Graul Ph.D. President
Rhonda M. Chicko Chief Financial Officer
Dr. Todd Milne Ph.D. Senior Vice President of External Innovation
Jessica Rennekamp Associate Director of Corporate Communications

Latest SEC Filings

Date Type Title
Mar 5, 2024 10-K Annual Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 5, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Dec 4, 2023 8-K Current Report
Dec 1, 2023 8-K Current Report
Nov 24, 2023 8-K Current Report
Nov 13, 2023 10-Q Quarterly Report